Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Asset disposition
Quarterly results
CC transcript
ACADIA PHARMACEUTICALS INC (ACAD) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/02/2023 8-K Quarterly results
Docs: "Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview - 2Q23 DAYBUE™ net product sales of $23.2 million - 2Q23 NUPLAZID® net product sales of $142.0 million - Expanded licensing agreement for trofinetide includes ex-North American rights SAN DIEGO, CA, August 2, 2023"
05/08/2023 8-K Quarterly results
Docs: "Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older on March 10, 2023 - Announced DAYBUE Availability on April 17, 2023 SAN DIEGO, CA, May 8, 2023"
08/08/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
Docs: "Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results - 1Q22 net sales of $115.5 million, an 8% increase over 1Q21 - Reiterating FY22 net sales guidance of $510 to $560 million - FDA Advisory Committee meeting to review sNDA for pimavanserin for the treatment of ADP scheduled for June 17, 2022 SAN DIEGO, CA, May 4, 2022"
02/28/2022 8-K Quarterly results
11/08/2021 8-K Quarterly results
Docs: "Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results - 3Q21 net sales of $131.6 million, a 9% increase over 3Q20 - FDA meeting scheduled to discuss next steps towards a resubmission of the pimavanserin sNDA"
08/04/2021 8-K Quarterly results
Docs: "Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results - 2Q21 net sales of $115.2 million, a 5% increase over 2Q20 - Fiscal year 2021 revenue guidance reduced to $480 to $515 million"
05/05/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
11/04/2020 8-K Quarterly results
Docs: "Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results - 3Q20 Net Sales of $120.6 Million, a 27% Increase Over 3Q19"
08/05/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
02/26/2020 8-K Quarterly results
10/30/2019 8-K Quarterly results
07/31/2019 8-K Quarterly results
Docs: "ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results - 2Q19 Net Sales Grew to $83.2 Million, a 46% Increase Over 2Q18 - 2019 Net Sales Guidance Increased to $320 Million to $330 Million"
05/01/2019 8-K Quarterly results
02/26/2019 8-K Quarterly results
Docs: "ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results - Fourth Quarter 2018 Net Sales Grew to $59.6 Million, a 37% Increase Over 4Q17 - Full Year 2018 Net Sales Grew to $223.8 Million, a 79% Increase Over Full Year 2017"
08/08/2018 8-K Quarterly results
Docs: "ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results -Second Quarter Net Sales Grew to $57.1 Million, Representing a 17% Sequential Increase Over 1Q18 and 87% Increase Over 2Q17"
05/04/2018 8-K Quarterly results
Docs: "ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results"
02/27/2018 8-K Quarterly results
Docs: "ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results"
11/07/2017 8-K Quarterly results
Docs: "Third Quarter 2017 Financial Results -Third Quarter Net Sales Grew to $35.6 Million -Company Raises Annual 2017 Net Sales Guidance to Between $124 Million and $127 Million SAN DIEGO, CA, November 7, 2017 – ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its unaudited financial results for the third quarter ended September 30, 2017. “Our results this quarter reflect strong growth for NUPLAZID for Parkinson’s disease psychosis,” said Steve Davis, ACADIA’s President and Chief Executive Officer. “We also recently advanced our clinical portfolio with the initiation of our Phase III study of pimavanserin for de..."
08/08/2017 8-K Quarterly results
05/09/2017 8-K Form 8-K - Current report
02/28/2017 8-K Form 8-K - Current report
11/07/2016 8-K Quarterly results
Docs: "ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results NUPLAZID® Net Product Sales Grew to $5.3 Million in the First Full Quarter of Commercialization Expanding Pimavanserin Clinical Program With Initiation of Studies for Alzheimer’s Disease Agitation and Adjunctive Treatment of Schizophrenia"
08/04/2016 8-K Quarterly results
Docs: "ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results Quarter highlighted by approval and launch of NUPLAZID™ in the United States, the first and only FDA-approved drug for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis"
05/05/2016 8-K Form 8-K - Current report
02/29/2016 8-K Form 8-K - Current report
11/05/2015 8-K Quarterly results
Docs: "ACADIA PHARMACEUTICALS REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS"
08/06/2015 8-K Quarterly results
Docs: "ACADIA PHARMACEUTICALS REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS"
05/07/2015 8-K Quarterly results
Docs: "ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS"
02/26/2015 8-K Quarterly results
Docs: "ACADIA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2014"
11/10/2014 8-K Quarterly results
Docs: "ACADIA PHARMACEUTICALS REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS AND UPDATES TIMING OF NUPLAZID™ NDA SUBMISSION"
08/05/2014 8-K Quarterly results
Docs: "ACADIA PHARMACEUTICALS REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy